- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Extending AI Therapy Beyond 5 Years Reduces Recurrence in HR-Positive Breast Cancer
June 6th 2016, 2:33am
Women who extended their adjuvant therapy with an aromatase inhibitor to 10 years after treatment for their early-stage HR-positive breast cancer reduced their risk of recurrence by more than a third and experienced no new toxicities or worsening of quality of life.
Dr. Balar on IMvigor 210 Results for Metastatic Urothelial Carcinoma
June 6th 2016, 2:31am
Arjun V. Balar, MD, assistant professor, Department of Medicine, co-leader of the Genitourinary Cancers Program, discusses updated results of cohort 1 of the IMvigor 210 study, which examined the efficacy of atezolizumab as first-line therapy in patients with cisplatin-ineligible locally advanced/metastatic urothelial carcinoma.
Survival in Recurrent GBM Surpasses Historical Results with Gene Therapy
June 6th 2016, 1:58am
A novel antiangiogenic gene therapy, added to bevacizumab, led to significantly better overall survival in recurrent glioblastoma multiforme compared with historical patients treated with bevacizumab alone, a small phase II trial showed.
Novel Gastric Cancer Immunotherapy Scores Robust Phase II Results
June 6th 2016, 12:50am
IMAB362 reduced the risk of death or progression by approximately 50% when added to standard chemotherapy for patients with CLDN18.2-positive advanced gastric cancers.
Nivolumab/Ipilimumab Combo Active in Microsatellite Instability-High mCRC
June 6th 2016, 12:27am
Nivolumab (Opdivo) as a monotherapy and in combination with ipilimumab (Yervoy) demonstrated promising antitumor activity in patients with high microsatellite instability (MSI-H) metastatic colorectal cancer.
Rovalpituzumab Tesirine Shows Promising Efficacy for SCLC
June 6th 2016, 12:22am
Treatment with rovalpituzumab tesirine demonstrated single-agent activity and a manageable safety profile for patients with recurrent/refractory small cell lung cancer.
Daratumumab Combo Shows Unprecedented PFS Benefit in Multiple Myeloma
June 5th 2016, 9:44pm
Adding daratumumab to bortezomib and dexamethasone reduced the risk of progression or death by 61%, and doubled response rates compared with the standard 2-drug regimen alone for patients with recurrent or refractory multiple myeloma.
Adding Temozolomide to Radiotherapy Is Effective and Tolerable in Older Adults With Glioblastoma
June 5th 2016, 9:03pm
Adding temozolomide to short-course radiotherapy after surgery boosted overall survival by nearly 2 months, bringing 1-year survival rates up from 22.2% to 37.8% for elderly patients with glioblastoma.
Dr. Palumbo on CASTOR Trial Results in Multiple Myeloma
June 5th 2016, 8:02pm
Antonio Palumbo, MD, chief, Myeloma Unit, Department of Oncology, Section of Hematology, University of Torino, Italy, discusses the phase III results of the CASTOR trial, which was a randomized controlled study examining the efficacy of daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Nivolumab/Ipilimumab Frontline Response Nears 60% in PD-L1+ NSCLC
June 5th 2016, 6:34pm
Upfront treatment with the combination of nivolumab and ipilimumab demonstrated an objective response rate of 57% in patients with PD-L1-positive advanced non–small cell lung cancer.
Final Phase III Data Uphold CPX-351 Survival Benefit in AML
June 5th 2016, 7:42am
CPX-351 reduced the risk of death by 31% compared with cytarabine and daunorubicin (7+3) for older patients with high-risk, secondary AML.
Adding 4-1BB Agonist to Pembrolizumab Safe, Effective Across Solid Tumors
June 5th 2016, 6:59am
The combination of the 4-1BB agonist utomilumab and the PD-1 inhibitor pembrolizumab was safe and effective as a treatment for patients with advanced solid tumors.
Dr. Hainsworth on Selecting Therapy Based on Genetics
June 5th 2016, 2:55am
John D. Hainsworth, MD, co-founder; principal investigator, Sarah Cannon Research Institute, discusses the results of the MyPathway trial, which was an open-label, phase IIa umbrella basket study.
Dr. Cavo on Upfront ASCT in Multiple Myeloma
June 5th 2016, 2:48am
Michele Cavo, MD, professor, Seràgnoli Institute of Hematology Bologna University School of Medicine, discusses the results of the phase III EMN02/HO95 MM trial, which compared the efficacy of upfront autologous stem cell transplantation versus novel agent-based therapy for the treatment of patients with multiple myeloma.
Nivolumab Survival Benefit Sustained in Long-Term NSCLC Outcomes
June 5th 2016, 2:40am
Two-year follow-up data showed sustained improvements in overall survival with nivolumab in pretreated patients with either nonsquamous or squamous non–small cell lung cancer in updated findings from the phase III CheckMate-057 and -017 trials.
Nivolumab Safe, Effective in Early Stage Glioblastoma Study
June 5th 2016, 2:07am
Single-agent nivolumab demonstrated encouraging signs of activity with a mild adverse event profile for patients with recurrent glioblastoma multiforme.
Molecular Targeting Yields Responses in 12 Cancers in Off-Label Indications
June 5th 2016, 12:43am
Treating patients based on the presence of molecular abnormalities regardless of tumor type proved to be a promising strategy in an ongoing phase IIa umbrella basket study.
Large Study Gives Boost to Liquid Biopsy Testing for Mutations
June 5th 2016, 12:16am
The liquid biopsy testing method correlated closely with mutations described in databases and in some cases from tumor biopsies.
Patient-Driven Research Project Aims to Advance Metastatic Breast Cancer Treatment
June 5th 2016, 12:10am
Researchers are hoping that a new nationwide effort to encourage patients to share their tumor samples and clinical information will lead to new discoveries and better treatments.
Combining Atezolizumab With OX40 Agonist Shows Promise in Solid Tumors
June 4th 2016, 10:15pm
A combination regimen of the PD-L1 inhibitor atezolizumab (Tecentriq) and the investigational OX40 agonist MOXR0916 was well tolerated and showed early signs of of antitumor activity in solid tumors.